Essa Pharma INC 8-K filings

ESSA Pharma Inc. announced the completion of its acquisition by XenoTherapeutics, with shareholders receiving cash and contingent value rights.

ESSA Pharma Inc. securityholders overwhelmingly approved the acquisition by XenoTherapeutics Inc. via a statutory plan of arrangement.

ESSA Pharma Inc. announced a class action lawsuit was filed against it on September 30, 2025, alleging breach of contract and promissory estoppel related to disclosures made in an August 14, 2025 8-K filing.

ESSA Pharma Inc. received an amended Interim Order from the Supreme Court of British Columbia, approving key dates for its special meeting and court hearing related to the business combination with XenoTherapeutics Inc.

ESSA Pharma Inc. announced an amendment to its Business Combination Agreement with XenoTherapeutics, reducing the expected cash distribution to shareholders at closing and introducing contingent value rights.

ESSA Pharma Inc. has adjourned its special meeting to approve the acquisition by XenoTherapeutics, Inc. to September 29, 2025, to discuss revised financial terms.

ESSA Pharma Inc. announced a correction to the due bill trading period for its previously announced US$80 million capital distribution, clarifying that shares traded ex-dividend as of August 25, 2025.

ESSA Pharma Inc. announced the ex-dividend date and due bill trading procedures for its $80 million return of capital distribution as part of its winding-up and acquisition by XenoTherapeutics, Inc.

ESSA Pharma Inc. announced a US$80 million capital distribution to shareholders ahead of its acquisition by XenoTherapeutics, with shareholders expected to receive approximately US$1.91 per share in total.

ESSA Pharma Inc. has informed shareholders about the potential U.S. and Canadian federal income tax consequences of a planned cash distribution tied to its business combination with XenoTherapeutics, Inc.

ESSA Pharma Inc. announced its intent to seek a British Columbia Supreme Court order on August 5, 2025, to facilitate its merger with XenoTherapeutics, including an initial cash distribution to shareholders.

ESSA Pharma Inc. has entered into a definitive agreement to be acquired by XenoTherapeutics, Inc., with financing from XOMA Royalty Corporation, in an all-cash transaction that includes contingent value rights for shareholders.

ESSA Pharma announces its financial results for the second fiscal quarter ended March 31, 2025, while continuing to evaluate strategic options to maximize shareholder value following the discontinuation of its clinical trials.

ESSA Pharma successfully held its 2025 annual general meeting, with shareholders voting on key proposals including the election of directors and the appointment of auditors.

ESSA Pharma reports a net loss of $8.5 million for the first fiscal quarter ended December 31, 2024, as it explores strategic options following the termination of its clinical trials.

ESSA Pharma has terminated its masofaniten clinical trials and is exploring strategic options after a Phase 2 study failed to meet its primary endpoint.

ESSA Pharma Inc. has terminated its license agreement with the British Columbia Cancer Agency and the University of British Columbia, effective December 12, 2024.

ESSA Pharma has adopted a new severance plan for its executive officers, replacing previous cash severance benefits with a structured plan that includes cash severance and benefits continuation.

ESSA Pharma has terminated its Phase 2 clinical trial of masofaniten combined with enzalutamide for prostate cancer due to a lack of efficacy compared to enzalutamide alone.

ESSA Pharma announced updated clinical data showing that masofaniten in combination with enzalutamide continues to be well-tolerated and demonstrates durable reductions in PSA levels in patients with metastatic castration-resistant prostate cancer.

ESSA Pharma is progressing its prostate cancer drug development programs, with key data readouts expected throughout the remainder of 2024 and into 2025, and reports a net loss of $7.2 million for the third quarter of 2024.

ESSA Pharma's combination therapy shows strong results in prostate cancer patients, with a cash runway extending beyond 2025.

ESSA Pharma Inc. successfully held its 2024 annual general meeting, with shareholders voting on key proposals including the election of directors and approval of an incentive plan amendment.

ESSA Pharma's combination therapy shows significant PSA reductions in prostate cancer patients, with a cash runway extending beyond 2025.

ESSA Pharma reported promising updated data from its Phase 1/2 study of masofaniten combined with enzalutamide, showing significant PSA reductions in patients with metastatic castration-resistant prostate cancer.